BioMarin Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio
BioMarin Pharmaceutical (San Rafael, CA): 7 reconciled FDA prescription therapies (7.4% 2025 to 2030 cliff risk), $331.2M 2024 CMS Part D & Medicaid spend, and 41 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | San Rafael, CA |
| Reconciled FDA Portfolio Therapies | 7 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 7.4% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $331.2M |
| 2024 Medicare Part D Spend | $56.0M |
| 2024 Medicaid Spend | $275.2M |
| California HCAI SB 17 Filings | 41 WAC filings (max 21.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.